Suffering in silence: COPD patients face frequent symptoms, dissatisfaction with meds, but don't talk to docs — survey

Beth Snyder Bulik

Senior Editor

Most COPD patients suffer symptoms daily, but contrary to the typical advice doled out in pharma TV commercials, they’re not talking to their doctors about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Suffering in silence: COPD patients face frequent symptoms, dissatisfaction with meds, but don't talk to docs — survey

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Suf­fer­ing in si­lence: COPD pa­tients face fre­quent symp­toms, dis­sat­is­fac­tion with meds, but don't talk to docs — sur­vey

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Suffering in silence: COPD patients face frequent symptoms, dissatisfaction with meds, but don't talk to docs — survey

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.